Skip to main content

Table 6 FAB classification: OS of patients with MDS or AML receiving azacitidine front-line

From: Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

FAB diagnosis n Median OS, mo 95 % CI, mo p value
AML30+
MDS-RAEB-t
MDS-RAEB
111
101
131
10.9
12.8
24.4
7.5–14.3
10.1–15.5
18.5–30.3
<0.001a
AML30+
MDS-RAEB-t
111
101
10.9
12.8
7.5–14.3
10.1–15.5
0.376
MDS-RAEB-t
MDS-RAEB
101
131
12.8
24.4
10.1–15.5
18.5–30.3
<0.001b
  1. aHR = 1.248; 95 % CI 1.249, 1.634
  2. bHR = 2.185; 95 % CI 1.557, 3.066
  3. FAB French-American-British, OS overall survival, MDS myelodysplastic syndrome, AML acute myeloid leukaemia, CI confidence interval, RAEB refractory anaemia with excess blasts, HR hazard ratio